Clinical factors associated with response or survival after chemotherapy in patients with Waldenström macroglobulinemia in Korea.

Publisher: Hindawi Pub. Co Country of Publication: United States NLM ID: 101600173 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2314-6141 (Electronic) NLM ISO Abbreviation: Biomed Res Int Subsets: MEDLINE

Original Publication: New York, NY : Hindawi Pub. Co.

Prognosis* ; Survival Analysis*; Waldenstrom Macroglobulinemia/*drug therapy; Adult ; Aged ; Aged, 80 and over ; Female ; Humans ; Male ; Middle Aged ; Republic of Korea ; Retrospective Studies ; Treatment Outcome ; Waldenstrom Macroglobulinemia/epidemiology ; Waldenstrom Macroglobulinemia/pathology

Waldenström's macroglobulinemia (WM) is a B-cell proliferative malignancy characterized by immunoglobulin M monoclonal gammopathy and bone marrow infiltration by lymphoplasmacytic cells. Clinical features and cytogenetics of WM in Asia including Republic of Korea remain unclear. Moreover, no study has reported treatment outcomes in patients with WM treated with novel agent combined with conventional chemotherapy. This study investigated clinical features and assessed treatment outcomes with novel agent and conventional chemotherapy in Republic of Korea. Data from all (n = 71) patients with newly diagnosed WM at 17 hospitals who received chemotherapy between January 2005 and December 2012 were collected retrospectively. The median age of patients was 66 years (range: 37-92 years) and male to female ratio was 5 : 1. Patients treated with novel agent combined chemotherapy displayed higher overall response rate (ORR) compared to conventional chemotherapy alone (92.9% versus 52.6%, P = 0.006). The 5-year overall survival rate was 62.6% (95% confidence interval: 34.73-111.07). Use of novel agents produced higher ORR but survival benefit was not apparent due to the small number of patients and short follow-up duration. Further studies are needed to confirm the efficacy of novel agents in patients with WM.

Cancer Genet Cytogenet. 2006 Sep;169(2):150-3. (PMID: 16938573)
Clin Lymphoma Myeloma Leuk. 2011 Feb;11(1):130-2. (PMID: 21454213)
Blood. 2008 Dec 1;112(12):4452-7. (PMID: 18713945)
Clin Cancer Res. 2009 Jan 1;15(1):355-60. (PMID: 19118065)
Leuk Lymphoma. 2004 Oct;45(10):2047-55. (PMID: 15370249)
Cancer. 2012 Jan 15;118(2):434-43. (PMID: 21732338)
Clin Lymphoma Myeloma. 2009 Mar;9(1):62-6. (PMID: 19362976)
Ther Adv Hematol. 2013 Apr;4(2):133-48. (PMID: 23610620)
Clin Lymphoma. 2005 Mar;5(4):273-7. (PMID: 15794864)
Blood. 2009 Apr 16;113(16):3673-8. (PMID: 19015393)
Leukemia. 2006 Sep;20(9):1634-6. (PMID: 16838026)
Blood. 2009 Apr 30;113(18):4163-70. (PMID: 19196866)
Blood. 2007 Jun 15;109(12):5096-103. (PMID: 17303694)
Am J Hematol. 2013 Aug;88(8):703-11. (PMID: 23784973)
Cancer. 1998 Aug 15;83(4):806-12. (PMID: 9708949)
Korean J Intern Med. 2004 Sep;19(3):137-40. (PMID: 15481603)
Blood. 2009 Sep 17;114(12):2375-85. (PMID: 19617573)
Semin Oncol. 2003 Apr;30(2):110-5. (PMID: 12720118)
Blood. 2000 Aug 1;96(3):852-8. (PMID: 10910896)
J Clin Oncol. 2009 Aug 10;27(23):3830-5. (PMID: 19506160)
J Clin Oncol. 2010 Mar 10;28(8):1422-8. (PMID: 20142586)
Cancer Genet Cytogenet. 2010 Mar;197(2):117-21. (PMID: 20193844)
Br J Haematol. 2001 Dec;115(3):575-82. (PMID: 11736938)
J Clin Oncol. 2007 Aug 1;25(22):3344-9. (PMID: 17577016)
Int J Cancer. 2014 Jan 1;134(1):174-80. (PMID: 23784625)
Blood. 2007 Jul 15;110(2):695-708. (PMID: 17389762)
Lancet. 2013 Apr 6;381(9873):1203-10. (PMID: 23433739)
Best Pract Res Clin Haematol. 2005;18(4):747-65. (PMID: 16026748)
Clin Lymphoma Myeloma Leuk. 2011 Feb;11(1):68-73. (PMID: 21454194)
Semin Oncol. 2003 Apr;30(2):226-30. (PMID: 12720141)
Blood. 1994 May 15;83(10):2939-45. (PMID: 8180389)
Ann Hematol. 2010 Oct;89(10):1011-8. (PMID: 20449747)
Semin Hematol. 2011 Apr;48 Suppl 1:S24-36. (PMID: 21530769)

Date Created: 20140705 Date Completed: 20150224 Latest Revision: 20220321

20231215

PMC4065725

10.1155/2014/253243

24995279